Parker-Hannifin PH

EARNINGS BANNER — REPORTS IN TWO DAYS

Parker-Hannifin reports fiscal 2026 fourth-quarter and full-year results on 2026-08-06, two calendar days after this dive is struck. Vendor consensus is adjusted EPS $8.26 and revenue $5,573.7M, against year-ago actuals of $7.69 and $5,243M — implied growth of +7.4% and +6.3%. The print also carries the first FY2027 guide, and is the first occasion since the 30 April 10-Q for management to address Filtration Group timing. The verdict below is set with that two-day gap as an explicit input. A dive struck 48 hours before a fiscal-year-end print on a stock at the 91st percentile of its annual range is, by construction, not an entry recommendation.

Reference table

1. What the business is, and how the disclosure works

Parker describes itself in the 10-K as "a global leader in motion and control technologies. Leveraging a unique combination of interconnected technologies, we design, manufacture, and provide aftermarket support for highly engineered solutions that create value for customers primarily in aerospace & defense, in-plant & industrial equipment, transportation, off-highway, energy, and HVAC & refrigeration markets around the world." Chief executive Jennifer A. Parmentier; approximately 57,950 employees per the vendor profile; Cleveland, Ohio; NYSE-listed since well before the 1980 date the vendor records as an IPO.

Two reportable segments, and the vendor gets this exactly right.

• Diversified Industrial — an aggregation of business units selling sealing and shielding, filtration, fluid connectors, hydraulics, pneumatics, engineered materials and thermal management into industrial equipment, transportation, off-highway, energy and HVAC/refrigeration. Sold direct to OEMs and through independent distributors. $13.665B in FY2025, 68.8% of revenue.
• Aerospace Systems — airframe and engine components and systems for commercial transport, defence fixed wing, business jets, regional transport, helicopters and energy applications. $6.185B in FY2025, 31.2% of revenue.

The seg_prod block reconciles exactly: $13,665M + $6,185M = $19,850M, matching the reported FY2025 revenue of $19,850M to the dollar. No missing segment, no double count.

seg_geo reconciles exactly as well — North America $13,406M + Europe $3,862M + Asia Pacific $2,364M + Latin America $218M = $19,850M. This is one of the cleanest vendor-to-filing reconciliations in the batch, and the home market is present — North America is 67.5% of revenue, which is the specific failure mode (SYK, DHR, BMY) that this check exists to catch. It passes. Note that the FY2017 and FY2018 rows of both blocks contain only North America and are structurally incomplete; they are not used.

The transformation, in one table

The mechanism is Meggitt. Parker paid $6.673B net for Meggitt plc in fiscal 2023 — the cf_a block shows acquisitionsNet of −$6.673B in FY2023, which is the clearest single number in the cash-flow series. Aerospace revenue went from $2.520B to $4.360B in that year and to $6.185B by FY2025. Whatever one thinks of the price, the deal changed what Parker is. It also explains the balance sheet: goodwill and intangibles of $18.5B against total assets of $30.7B, and tangible book value per share of negative $30.94.

Backlog — the forward-looking disclosure that matters

Backlog at 31 March 2026 was $12.5B against $11.0B at 30 June 2025 — a 13.6% increase in nine months — of which approximately 67% is expected to convert to revenue within twelve months. The 10-K notes that at June 2025 the equivalent figure was 71%, so the book is lengthening slightly. Aerospace backlog has risen every period shown, and the 10-Q attributes the March-quarter increase to "orders exceeding shipments in the commercial and defense OEM market segments, as well as the commercial aftermarket."

2. The corporate action the payload does not contain

This is the most important finding in this dive and it comes entirely from the filings.

> "On November 11, 2025, the Company announced that it has agreed to acquire Filtration Group Corporation ('Filtration Group') from Madison Industries for approximately $9.25 billion in cash. ... The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals, and is expected to close within 12 months from the announcement date."

> — 10-Q filed 2026-05-01, Note 4

> "On December 10, 2025, we entered into a 364-Day Term Loan Agreement and a Three-Year Term Loan Agreement, which provide for senior unsecured delayed draw term loan facilities in aggregate principal amounts of $5.25 billion and $2.50 billion, respectively. ... As of March 31, 2026, we have not borrowed any funds under the Filtration Group Credit Facilities."

> — 10-Q filed 2026-05-01, liquidity discussion

> "We expect to fund the transaction with a combination of new debt, including borrowings under the Filtration Group Credit Facilities and cash."

What the vendor payload contains about this: nothing. There is no field in quote, profile, km_ttm, ratios_ttm, bal_a or est that reflects a $9.25B pending cash acquisition or $7.75B of committed but undrawn term loans. bal_a ends at 30 June 2025, five months before the announcement. km_ttm.enterpriseValueTTM of $134.266B is market capitalisation plus the 31 March 2026 reported net debt of $9.106B — arithmetically correct, and correctly using the latest quarter rather than the stale annual, but structurally incomplete for a company that has signed a merger agreement for $9.25B of cash.

The pro-forma arithmetic, stated as arithmetic:

Two honest caveats on that table. First, Filtration Group's own revenue and EBITDA are not disclosed in any Parker filing in this archive, so the pro-forma leverage denominator is an assumption, not a datum. The ~$750M figure is what a $9.25B enterprise price implies at roughly 12x, which is a typical multiple for a filtration asset — it is illustrative and labelled as such, and no conclusion in this dive rests on it. Second, the split between new debt and cash is not disclosed; Parker held $476M of cash at 31 March 2026, so the overwhelming majority must be debt.

Why it matters beyond the leverage line. The 364-day tranche is $5.25B — more than half the consideration, maturing one year after first draw. Parker's stated financing preference is different: "We primarily utilize unsecured medium-term notes and senior notes to meet our financing needs." Bridging $5.25B into the bond market inside twelve months is a refinancing event on a scale Parker has not done since Meggitt, and it will happen at whatever rates prevail then.

And there is a naming trap inside the payload itself, worth flagging because it is exactly the class of error this process exists to catch. The insider block records transactions by "Jacobson Matthew A., officer: VP & Pres.-Filtration Grp." That is the head of Parker's own existing Filtration Group business unit, not an executive of the acquisition target Filtration Group Corporation. The two are unrelated entities sharing a name. We checked; they are not the same thing.

3. Growth, margins and the tax distortion in the reported numbers

Quarterly, from inc_q, cross-checked against the 10-Q income statement:

Revenue growth is accelerating: +3.7%, +9.1%, +10.6%. Nine-month sales were $15.744B against $14.607B, +7.8%, of which the 10-Q attributes approximately $242M to currency and $161M to the Curtis acquisition, with $146M of divestiture drag. Strip all three and organic nine-month growth is roughly +5.4%.

Now the trap in the GAAP line, which the filing settles. Net income in the March 2026 quarter was $904M against $962M a year earlier — a 6.0% decline on a 10.6% revenue increase. That is not operational. The 10-Q income statement shows income before taxes of $1,119M against $995M (+12.5%) and income taxes of $215M against $33M. The year-ago quarter carried a 3.4% effective tax rate; the current quarter carried 19.2%. Nine-month pre-tax income was $3,223M against $3,036M (+6.2%) while net income was $2,557M against $2,609M (−2.0%), for the same reason plus a $253M prior-year gain on sale of businesses that does not repeat. Anyone reading Parker's GAAP net income year on year without opening the filing would conclude the business is deteriorating. It is not. This is why the diluted EPS line reads $19.95 for nine-month FY2026 against $19.97 for FY2025 — dead flat — while adjusted EPS is up 8-9% every quarter.

Segment operating income, nine months to March (10-Q):

Aerospace contributed $277M of the $442M increase in segment operating income — 63% of the growth from 33% of the revenue. The 10-Q attributes it to "higher sales volume, aftermarket profitability, as well as benefits from cost containment initiatives."

One negative worth naming. Diversified Industrial's quarterly margin went the wrong way: 22.5% in Q3 FY2026 against 23.0% a year earlier, which the 10-Q attributes to "unfavorable product mix, higher business realignment charges, higher amortization expense of acquired intangibles, as well as increased material costs offset by favorable pricing." Realignment charges in that segment were $29M in the quarter against $13M — more than double. The nine-month margin is still up, but the quarterly direction reversed.

4. Balance sheet, and the enterprise-value rebuild

Filing-verified, 31 March 2026 (10-Q filed 2026-05-01) — this is the most recent audited-adjacent balance sheet, and the vendor's bal_a stops nine months earlier at 30 June 2025:

A vendor-versus-filing discrepancy, disclosed. The vendor's bal_a for 30 June 2025 reports shortTermDebt of $1,838M and capitalLeaseObligations of $256M, summing with long-term debt of $7,546M to a totalDebt of $9,640M. The 10-Q's own comparative column for 30 June 2025 shows $1,791M current and $7,494M long-term, total $9,285M. The vendor reports $9,640M; the filing shows $9,285M; the $355M difference is the finance-lease and other-obligation treatment. We use the filing. This is the GLW lease-double-counting pattern in a milder form, and it does not change any conclusion — but the rule is that the filing wins and the dive says so.

The enterprise value, and a verified-clean finding. km_ttm.enterpriseValueTTM is $134,265,654,041. Market capitalisation is $125,159,654,041. The difference is exactly $9,106,000,000 — the 10-Q's 31 March 2026 net debt to the dollar. The vendor is using the current quarter, not the stale annual, and it is right. No short-term-investments omission (Parker holds none), no lease double-count in the EV line, no residual. We accept the vendor EV of $134.27B for the reported balance sheet, and separately present the ~$143.5B pro-forma figure for the pending acquisition.

Trailing EBITDA — the vendor's construction, disclosed and used with a caveat. ratios_ttm.ebitdaMarginTTM of 26.82% on TTM revenue of $20.987B gives $5.629B, and netDebtToEBITDATTM of 1.618x against net debt of $9.106B independently confirms it. We reconstructed it: trailing pre-tax income $4,294M + interest $405M + D&A $930M = $5,629M. It reconciles exactly. But note what it contains: Parker's income statement puts "Other expense (income), net" below operating income, and it was a $268M net income item in the nine months to March 2026 and a $456M net income item in FY2025 (containing pension credits, joint-venture earnings and, in FY2025, a $253M gain on business sales). EBITDA built from pre-tax income therefore includes non-operating income that EBITDA built from operating income does not. On the stricter basis — trailing operating income $4,379.5M plus D&A $930M — trailing EBITDA is $5,309.5M and EV/EBITDA is 25.3x, not 23.9x. We show both and label which is which.

What the balance sheet actually says. Reported leverage of 1.62x is comfortable and interest coverage of 10.8x is comfortable. The problem is the composition and the direction. Tangible equity is negative $3.912B; km_ttm.intangiblesToTotalAssetsTTM is 60.4%; the current ratio is 1.13x and the quick ratio 0.66x; commercial paper outstanding was $2.1B at 31 March 2026 against a $3.75B programme, leaving $1.7B available under the revolver. Into that, Parker is adding $9.25B of cash consideration. The vendor's own composite rating already scores Parker 2 out of 5 on debt-to-equity and 1 out of 5 on price-to-book, dragging the overall grade to B+ / 3 — and those scores were computed before the acquisition, on the reported balance sheet.

5. Cash flow and capital returns

Free cash flow has compounded 14.7% a year over the period and the FCF margin has widened 290 basis points. Capex is 2.2% of revenue (capexToRevenueTTM 1.99%), which is what an assembly-and-engineering business rather than a heavy-manufacturing one looks like. incomeQualityTTM is 1.177 — operating cash flow comfortably exceeds net income, the healthy direction.

The buyback stepped up hard in FY2025 and has continued. $1.766B in FY2025 against $332M in FY2024, and the treasury-share balance shows a further $1.480B in the nine months to March 2026 ($7,495M to $8,975M at cost). Annualised, that is roughly 1.6% of market capitalisation. Whether it survives Filtration Group is a genuine open question — $9.25B of cash consideration is roughly five years of the current repurchase rate, and the company has committed to fund it with "new debt and cash."

Dividend, and a vendor labelling correction. The vendor reports lastDividend: 7.4 and dividendPerShareTTM: 7.40, yielding 0.745%. That $7.40 is the trailing-twelve-month total, not the last declared dividend. The 10-Q gives the actual sequence: "We declared a quarterly cash dividend of $1.80 per share on January 22, 2026 ... Additionally, we declared a quarterly cash dividend of $2.00 per share on April 23, 2026, payable on June 5, 2026, increasing our annual dividend per share paid to shareholders for 70 consecutive fiscal years." Three quarters at $1.80 plus one at $2.00 is exactly $7.40. The forward run-rate is $8.00 annualised — a 0.81% yield, not 0.745%. The 10-K adds: "Cash dividends have been paid for 300 consecutive quarters" as at June 2025, which the 10-Q updates to 303. Payout ratio is 26.3%.

Total shareholder yield is therefore roughly 2.4% (0.81% dividend plus ~1.6% buyback), with the buyback leg at risk from the acquisition. This is not an income story.

6. Valuation — priced in or room?

At $992.65 (market cap $125.16B, 126.0M shares, enterprise value $134.27B reported / ~$143.5B pro-forma):

Estimate coverage is good in the near years and thin beyond. 16-18 analysts on FY2026, 14-16 on FY2027, 6 on FY2028 EPS, and ONE on FY2029 and FY2030 EPS. The FY2029 and FY2030 rows are excluded from every conclusion in this dive.

The est block passes its most important test and fails another, and both matter. The epsAvg row is verifiably sound: FY2026's $31.305 equals the three reported adjusted quarters ($7.22 + $7.65 + $8.17 = $23.04) plus the Q4 estimate of $8.26, to the cent. That is as clean a validation of epsAvg as this process gets, and it is why all forward valuation here runs on EPS. But ebitdaAvg and ebitAvg are fabricated on a fixed ratio and are rejected in full: ebitdaAvg is exactly 36.70% of revenueAvg in every year from FY2024 to FY2030, and ebitAvg is exactly 31.45% in the same years. Against actuals, FY2025's ebitdaAvg of $7.237B is 33% above the $5.423B Parker's own income statement supports. This is the APP/CVS/ISRG signature named in the data contract, and Parker is a clean example of it.

A materially important question about what the consensus covers. Consensus revenue of $22.714B for FY2027 is +6.5% on FY2026E — a growth rate consistent with organic mid-single-digit expansion and inconsistent with the addition of a business large enough to cost $9.25B. We conclude, and label as our inference rather than a datum, that the published consensus does not include Filtration Group. If the deal closes in FY2027, both the revenue line and the interest-expense line will have to be restruck, and the forward multiples above will change basis. A reader who buys at 29.1x FY2027E is buying a multiple computed on a company that will not exist in that form.

Peer context. The vendor peer set is a reasonable industrials cohort — Cummins ($87.8B), Emerson ($89.0B), Illinois Tool Works ($84.9B), Trane ($103.9B), 3M ($93.6B), plus defence primes (General Dynamics, Lockheed, Northrop) and Howmet Aerospace ($115.3B), which is also in this batch. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn. What can be observed: Parker at $125.16B is the largest of the pure industrials listed, and more than half its incremental profit growth now comes from a segment whose closest comparable in the peer set is Howmet, not Emerson.

6a. What today's price assumes (the inversion)

At $992.65 — 29.1x the FY2027 consensus and 26.4x FY2028 — the price embeds the following falsifiable claims:

• Revenue reaches $22.714B in the twelve months to June 2027 and $24.392B by June 2028. (Consensus; 16 and 12 analysts on revenue.) That is +6.5% then +7.4%, against a company that grew −0.4% in FY2025 and is tracking +7.8% for the nine months to March 2026. The nearest check is the 2026-08-06 print and the FY2027 guide attached to it.
• Adjusted EPS reaches $34.06 in FY2027 and $37.59 in FY2028 — +8.8% then +10.4% — (consensus; 14 and only 6 analysts). Note the EPS growth barely exceeds the revenue growth, which means consensus is modelling almost no further margin expansion. That is the conservative part of the estimate stack.
• Aerospace Systems operating margin holds at or above 25%. (Our number; the nine-month actual is 25.4%, against 22.9% a year earlier and 23.3% for FY2025.) Aerospace supplied 63% of the nine-month growth in segment operating income from 33% of revenue; if that margin normalises toward 23%, roughly $120M of annual operating income disappears at current volumes.
• The market keeps paying 26-29x forward earnings for a business compounding EPS at 9-10%. (Our number.) At 24x FY2028E the stock is $902; at 30x it is $1,128. The multiple is where the variance lives, and Parker's own history shows it moves a long way — the stock earned $16.23 in FY2023 and $27.52 in FY2025, a period over which the multiple expanded as well as the earnings.
• The $9.25B Filtration Group acquisition closes, integrates, and pro-forma leverage near 2.9x is not penalised. (Filing-confirmed transaction; our inference that consensus excludes it.) This is the most fragile assumption in the price, precisely because it is invisible: no screen shows it, the consensus revenue line appears not to contain it, and the $5.25B 364-day tranche must be refinanced within a year of first draw. The falsifier is public and dated — the outside closing date implied by the 10-Q is around 2026-11-11.

6b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: EPS growth (+10.4%, from FY2027E $34.06 to FY2028E $37.59) + multiple drift (COMPRESSION, from 29.1x to roughly 27x on the respective forward year, −7%) + shareholder yield (+2.4%, with the buyback leg at risk) ≈ +5% to +6%.

Our base assumes mild multiple compression, and the reason is leverage rather than growth. Parker's growth profile is stable — mid-single-digit revenue, high-single to low-double-digit EPS — so there is no deceleration argument of the kind that drives a de-rating at a semiconductor company. What changes is the balance sheet. A business at 1.6x net leverage with a 70-year dividend record and 10.8x interest coverage supports a premium industrial multiple. The same business at 2.9x, with $5.25B of one-year paper to refinance and negative tangible equity, ordinarily does not — and the market has historically discounted industrials through the deleveraging phase of a large acquisition. Parker itself is the precedent: the Meggitt deal closed in FY2023, and the stock spent that year at a materially lower multiple of forward earnings than it carries now.

Almost the entire expected return is earnings growth; the multiple is a headwind and the shareholder yield is small. If the multiple simply held at 29.1x on FY2028E the price would be $1,094 (+10.2%); at 24x it would be $902 (−9.1%). That 19-point spread on a single multiple assumption, against a base case of +0.7%, is the whole argument for Watch. The bull case at $1,225 requires modest expansion to 30x AND the FY2028 consensus high; the bear at $730 requires 21x and the consensus low.

6c. Variant perception (where we differ, what would surprise)

• We differ from every screen on the balance sheet, and the difference is $9.25 billion. Vendor netDebt, vendor enterpriseValueTTM, vendor netDebtToEBITDATTM and the vendor's composite rating all describe a company at 1.62x leverage with $134.27B of enterprise value. The filings describe a company that has signed a merger agreement for $9.25B of cash and arranged $7.75B of term loans to pay for it. Pro-forma enterprise value is closer to $143.5B and pro-forma leverage closer to 2.9x. This is not a modelling nuance; it is a fact in a filed document that no data field carries.
• We differ from consensus on what the FY2027 revenue line means. At +6.5% it reads organic. If Filtration Group closes inside fiscal 2027, revenue steps up and interest expense steps up with it, and neither is in the published number. A reader comparing Parker's 29.1x FY2027E against a peer's forward multiple is comparing a pre-deal Parker to a post-deal price.
• We do NOT differ on the operating business, and that is itself a finding. Aerospace mix, margin expansion, record backlog and re-accelerating industrial demand are all visible to everyone and all reflected in a stock 2.97% below its 52-week high at the 91st percentile of its range. The street's $1,062.25 is 7.0% up; our $1,000 is 0.7% up; the street's own low target of $950 is below the price. On the business, we have no edge.
• Positive surprise that would force a re-rate: an FY2027 guide on 2026-08-06 above roughly $23.0B of revenue or $35.00 of adjusted EPS; Aerospace margin printing above 26% in the June quarter; or Filtration Group closing with a majority of the consideration termed out into long bonds rather than the 364-day facility.
• Negative surprise that would break the thesis: an FY2027 guide below $22.0B of revenue or $33.00 of EPS; Aerospace margin below 24%; Diversified Industrial organic growth turning negative again after only three quarters positive; a regulatory delay or repricing of Filtration Group; or a drawdown of the full $5.25B 364-day tranche without a concurrent bond issue. The stock has no valuation cushion for any of these — 29.1x forward, 3% off the high, reporting in two days.

Synthos fair values

All three anchors are multiples of the FY2028 consensus adjusted-EPS distribution (mean $37.587, low $34.653, high $40.778 — 6 analysts, which is thin and is disclosed), cross-checked against the better-covered FY2027E of $34.059 (14 analysts).

• Bear ~$730 — 21x the FY2028 consensus LOW of $34.653. Cross-check: 21.4x FY2027E; roughly a 27% drawdown, in line with what Parker did through the last industrial destocking cycle. The scenario: Filtration Group closes into a weaker industrial market, leverage sits near 3x, the 364-day tranche refinances at a wider spread, Aerospace margin normalises toward 23%, and the multiple compresses to what a levered cyclical earns. −26.5%.
• Base ~$1,000 — 26.6x the FY2028 consensus MEAN of $37.587. Cross-check: 29.4x FY2027E, essentially the current multiple; EV/sales of 5.5x on FY2028E revenue. Sensitivity, stated openly: 25x gives $940, 28x gives $1,052. The whole answer lives in a 25-28x band. The scenario: revenue and EPS land on consensus, the deal closes and integrates without drama, and the multiple gives back a little for leverage. +0.7%, plus roughly 2.4% of shareholder yield.
• Bull ~$1,225 — 30x the FY2028 consensus HIGH of $40.778. Cross-check: 36.0x FY2027E. The scenario: aerospace aftermarket runs hotter than modelled, Filtration Group proves immediately accretive at a lower financing cost than feared, industrial organic growth reaches mid-single digits, and the market re-rates Parker toward an aerospace multiple rather than a machinery one. +23.4%.

Base is 0.7% above spot; asymmetry roughly 0.88:1 — more downside than upside on our own numbers. That is the arithmetic reason this is a Watch and not a Buy, and it is not a close call.

7. Knowledge base — three hits, two distinct claims, zero about Parker

Raw hits: 3. Entity matches: 3. Distinct claims after de-duplication: 2. Used as name-level conviction: 0. Used as supporting colour: 2. Discarded for collision: 6.

The primary sweep covered entity matches on Parker-Hannifin, Parker Hannifin, standalone Parker, Filtration Group, and a case-sensitive exact match on PH across all 51,928 distilled claims. Two supplementary text sweeps were run because "PH" and "Parker" are both flagged collision-prone.

The three raw hits, verbatim:

> 2025-07-20 · bullish · conviction 92 · horizon: thesis · entities: XOM, CVX, FCX, CAT, DE, PH · channel: jordi_visser · no named speaker · speaker_role: independent

> "Pounding the table on these megacap energy/industrial 'power' names — they've underperformed and trade very cheap two years out versus Mag 7/software, and are needed for the AI power buildout."

> 2026-02-27 · bullish · conviction 70 · horizon: thesis · entities: Carrier, Trane, Quanta Services, Parker Hannifin · channel: compound_and_friends · no named speaker

> "AI-derivative industrial-services names remain firmly in gear — the picks-and-shovels of the buildout, not defensive staples/healthcare."

> 2026-02-27 · bullish · conviction 70 · horizon: thesis · entities: Carrier, Trane, Quanta Services, Parker Hannifin · channel: compound_and_friends · no named speaker

> "AI-derivative industrials (HVAC, power, electrical services) are firmly in gear and reversing well off bear-market lows."

De-duplication. The second and third are the same claim, same date, same channel, same entity list, same stance and conviction, differing only in wording. They are one observation recorded twice, and counting them as two independent voices would be exactly the kind of inflation this process exists to prevent. We count two distinct claims.

Concentration sensitivity test — required, because compound_and_friends supplies 2 of 3 raw hits (67%). Removing that channel entirely leaves the jordi_visser claim, which is also a basket call — PH appears sixth in a list of six tickers, alongside two oil majors, a copper miner and two farm/construction equipment makers. The conclusion does not change under the sensitivity test, because both surviving positions say the same thing at different levels of specificity: PH is a member of a set of industrials expected to benefit from the AI power buildout. Neither claim asserts anything about Parker's segments, its margins, its backlog, its valuation, or — notably — the $9.25B acquisition that is the single most consequential fact about the company right now.

Attribution quality is mediocre. All three carry speaker: null and are attributed at channel level, the weakest sourcing the 4-lane attribution policy admits. The jordi_visser claim does carry speaker_role: independent, which at least rules out management voice; no claim in this lane carries a management role, so the half-weight management discount does not apply. The jordi_visser lane is a high-skill lane in the Synthos registry, and its conviction of 92 is the highest reading here — but a conviction of 92 attached to a six-name basket is a conviction about the basket.

Homograph discipline — six discards, listed with reasons.

Conclusion, stated as a finding. The Synthos knowledge base has no view on Parker-Hannifin. It has a thematic view that industrial suppliers to the AI power and data-centre buildout are attractive, and Parker is named as a constituent of that theme by two independent channels seven months apart. That is genuine thematic corroboration for the exponential-potential score and for nothing else. It is not name-level conviction, it does not justify a valuation premium, and — most tellingly — not one claim in the base is aware of the largest acquisition Parker has attempted since Meggitt. Conviction rating Low, breadth 2.

8. Data integrity — what we rejected and why

Nine findings. Parker's file is above average for internal consistency and below average for completeness, and the gap is entirely about the acquisition.

1. THE MAJOR FINDING — a $9.25B pending acquisition appears in no vendor field. The 10-Q filed 2026-05-01 discloses that Parker agreed on 2025-11-11 to acquire Filtration Group Corporation from Madison Industries for approximately $9.25 billion in cash, funded by a $5.25B 364-Day Term Loan and a $2.50B Three-Year Term Loan entered 2025-12-10 and undrawn at 31 March 2026. bal_a ends at 30 June 2025, five months before the announcement; km_ttm.enterpriseValueTTM, km_ttm.netDebtTTM equivalents, ratios_ttm.debtToEquityRatioTTM and the vendor rating block all describe the pre-deal company. We present both the reported and the pro-forma balance sheet, label which is which, and disclose that the Filtration Group EBITDA used in the pro-forma leverage ratio is an illustrative assumption because the filings do not disclose it.

2. est.ebitdaAvg and est.ebitAvg are fixed-ratio fabrications — REJECTED in full. ebitdaAvg is exactly 36.70% of revenueAvg in every year FY2024 through FY2030; ebitAvg is exactly 31.45% across the same span. Against actuals, FY2025's ebitdaAvg of $7.237B is 33.5% above the $5.423B the income statement supports, and FY2024's $7.335B is 45.9% above the reported $5.028B. The signature named in the data contract (APP 52.17%, CVS 4.208%, ISRG 36.13%, SYK 22.91%) is present here at 36.70%/31.45%. No forward valuation in this dive touches these rows.

3. est.epsAvg is verifiably sound — VALIDATED and used. The FY2026 epsAvg of $31.305 reconciles exactly to the three reported adjusted quarters from earn_cal ($7.22 + $7.65 + $8.17 = $23.04) plus the Q4 estimate of $8.26 = $31.30. All forward valuation runs on epsAvg and revenueAvg.

4. Estimate coverage collapses after FY2028 — later rows EXCLUDED. numAnalystsEps is 16 for FY2026, 14 for FY2027, 6 for FY2028, and ONE for both FY2029 and FY2030. The FY2029 and FY2030 rows are excluded from every conclusion. The FY2028 row is used for the fair-value anchors with its six-analyst coverage disclosed in the caveat.

5. bal_a total debt for FY2025 disagrees with the 10-Q comparative — filing used. Vendor: short-term debt $1,838M + long-term $7,546M + capital leases $256M = totalDebt $9,640M. The 10-Q's own 30 June 2025 column: $1,791M current + $7,494M long-term = $9,285M. The vendor reports $9,640M; the filing shows $9,285M; we use the filing. The $355M gap is finance-lease and other-obligation classification — the GLW pattern, milder. It does not change any conclusion, and the EV line is unaffected because the vendor builds EV from the March 2026 quarter, not the June 2025 annual.

6. km_ttm.enterpriseValueTTM is CORRECT — verified, stated as a clean finding. $134,265,654,041 minus market capitalisation of $125,159,654,041 is exactly $9,106,000,000, which is the 10-Q's 31 March 2026 net debt (total debt $9,582M less cash $476M) to the dollar. No short-term-investments omission (Parker holds none), no stale-annual substitution, no unexplained residual. The vendor EV is accepted for the reported balance sheet.

7. Trailing EBITDA is internally consistent but built on pre-tax income — used with both bases disclosed. ebitdaMarginTTM of 26.82% implies $5,629M, and netDebtToEBITDATTM of 1.618x independently confirms it. Reconstructed: pre-tax income $4,294M + interest $405M + D&A $930M = $5,629M, exact. But this includes roughly $353M of non-operating "other income, net" (pension credits, joint-venture earnings, and in the prior year a $253M gain on business sales). On an operating basis — operating income $4,379.5M + D&A $930M = $5,309.5M — EV/EBITDA is 25.3x rather than 23.9x. Both are shown and labelled.

8. lastDividend: 7.4 is the trailing-twelve-month total, not the last declared dividend — corrected from the filing. The 10-Q states dividends of $1.80 declared 22 January 2026 and $2.00 declared 23 April 2026. Three quarters at $1.80 plus one at $2.00 is exactly $7.40. The forward run-rate is $8.00 annualised, a 0.81% yield, not the 0.745% the vendor's TTM figure implies.

9. quote.yearHigh/yearLow disagree with tech.hi52/lo52 — tech used. Quote: $1,034.96 / $692.02. Tech: $1,023.02 / $697.13. Discrepancies of 1.2% and 0.7%. We use tech throughout for internal consistency with the moving averages and drawdown figures computed from the same close series. Note that tech.pct_from_hi and tech.max_dd_from_peak are both −2.97%, identical — this is the legitimate coincidence flagged in the defect list (the 252-day high and the six-year peak are the same recent price), not a defect.

Not defects, correctly reported and independently confirmed: seg_prod sums to $19,850M for FY2025, matching reported revenue exactly, with both reportable segments present and correctly named; seg_geo sums to $19,850M with North America, the 67.5% home market, present — the SYK/DHR failure mode is absent here; the FY2023 acquisitionsNet of −$6,672,903,000 matches the Meggitt purchase; interestCoverageRatioTTM of 10.81x is consistent with the debt and income figures; incomeQualityTTM of 1.177 correctly reflects operating cash flow exceeding net income; profile.currency is USD and inc_a[0].reportedCurrency is USD — no currency mixing. The FY2017 and FY2018 rows of seg_prod and seg_geo contain only partial data and are not used.

A payload naming trap, disclosed. The insider block lists "Jacobson Matthew A., officer: VP & Pres.-Filtration Grp." This is the head of Parker's own internal Filtration Group business unit and has nothing to do with Filtration Group Corporation, the $9.25B acquisition target. Two unrelated entities sharing a name inside the same file.

Non-equity tripwire — checked and passed. PH is common stock, $0.50 par value, NYSE-listed (10-Q cover page). The $992.65 price is not par-like; beta is 1.11; the dividend is variable and has risen for 70 consecutive years rather than being fixed; volume was 939,359 shares (~$932M of turnover); the 52-week band of $697.13 to $1,023.02 is a 47% range. This is common equity.

9. Technicals

• Price $992.65, down 0.49% on a day the market was broadly higher. −2.97% from the 52-week high of $1,023.02; +42.4% above the 52-week low of $697.13. Position within the annual range: 90.7th percentile.
• Moving averages, both supportive: +6.2% above a 50-day of $935.02; +9.1% above a 200-day of $909.54. Both rising, and the 50-day is above the 200-day.
• RSI 63.7 — strong but not overbought. MACD +11.98 — positive.
• Maximum drawdown from the six-year peak: −2.97%, i.e. the stock is essentially at its high.
• Relative performance, and it has two phases: 3-month +14.4% vs SPY +7.6% and QQQ +7.7% — strong outperformance; 6-month +4.3% vs SPY +11.1% and QQQ +15.7% — clear underperformance; 12-month +39.4% vs SPY +24.3% and QQQ +30.8%. The stock did nothing for three months, then ran 14% in three. The move is young.
• Sentiment: 24 buy, 13 hold, 1 sell across 38 analysts; consensus $1,062.25 (+7.0%), median $1,044, high $1,269 (+27.8%), low $950 — 4.3% BELOW spot.

What the technical picture does to the entry. This is a strong chart, and nothing here argues the trend is broken. What it does not offer is a discount. At the 91st percentile of the annual range, 3% from the high, with a base fair value 0.7% above the close and the lowest street target already below the price, there is no technical or valuation support beneath the position — and the company reports in two days. The setup rewards waiting for the print, not front-running it.

10. Insiders — eight transactions, four officers, one date, zero open-market activity

Every insider transaction in the file was filed 2026-04-24 for transactions dated 2026-04-22, priced at $954.43, in four matched pairs:

The reading, stated carefully because this table is easy to misread. Every disposition is coded F-InKind — shares withheld by the issuer to satisfy tax on the same day's restricted-stock vest. These are not open-market sales; the officer never receives them. Every acquisition is coded A-Award — a grant, not a purchase. The file therefore contains zero open-market purchases and zero open-market sales, which is a neutral signal and is reported as neutral. Four officers vesting on the same day at the same price in late April is the signature of a scheduled annual equity cycle.

What is worth noting is the size of the residual holdings: 1,839 to 9,560 shares, or roughly $1.8M to $9.5M. These are modest by the standards of a $125B company — the chief executive does not appear in the last eight transactions at all, so no inference about her position is available from this file. No signal either way.

11. Verdict, kill-criteria and flip conditions

Watch.

What is genuinely good, and none of it is disputed: a transformation from 15.9% aerospace in FY2022 to 32.8% in the nine months to March 2026, with Aerospace operating margin at 25.4% against 22.9% a year earlier; $12.5B of backlog against $11.0B nine months ago, with the Aerospace piece up 15.4% year on year; revenue growth re-accelerating +3.7%, +9.1%, +10.6% across fiscal 2026; free cash flow compounding to $3.341B at a 16.8% margin on 2.2%-of-revenue capex; 303 consecutive quarterly dividends and 70 consecutive annual increases, the rate raised to $2.00 per quarter on 23 April 2026; ROIC of 13.3% and interest coverage of 10.8x; and five consecutive adjusted-EPS beats averaging 6.3%.

What we are declining to pay for: 29.1x FY2027 consensus and 26.4x FY2028 for a business consensus expects to compound EPS at 8.8% then 10.4%; a stock 2.97% below its 52-week high at the 90.7th percentile of its annual range; a base fair value of $1,000 that is 0.7% above the close, against a street consensus of $1,062.25 whose own low estimate of $950 is already 4.3% below spot; a balance sheet with negative $3.9B of tangible equity and 60.4% of assets in goodwill and intangibles, about to absorb $9.25B of cash consideration funded in part by $5.25B of 364-day paper; and a knowledge-base lane of two distinct basket claims, neither about this company.

The distinction that matters. Parker is a better business than it was four years ago and the market knows it — that is what a 39.4% twelve-month return against SPY's 24.3% means. Our disagreement is not with the business; it is that the price now assumes both the operating improvement AND a clean, cheap, accretive $9.25B acquisition that no data feed we buy has heard of and whose closing date is unknown. When our own arithmetic puts fair value 0.7% above the price, the downside case is 26.5% and the upside case is 23.4%, and the company reports in 48 hours, the honest answer is to wait for the print and the guide. That is a Watch by arithmetic, not by hesitation.

Pre-registered KILL criteria — what would take this to Avoid:

• An FY2027 guide on 2026-08-06 below roughly $22.0B of revenue or $33.00 of adjusted EPS, either of which breaks the estimate stack the multiple rests on.
• Aerospace Systems operating margin below 24% in any quarter, reversing the mix benefit that supplied 63% of nine-month segment profit growth.
• Diversified Industrial organic growth turning negative again, after only three consecutive positive quarters and against a FY2025 that was −3.0%.
• Full drawdown of the $5.25B 364-day Filtration Group tranche without a concurrent long-bond issue, which would mean $5.25B of one-year refinancing risk sitting on a balance sheet with negative tangible equity.
• A regulatory challenge to, repricing of, or termination fee arising from the Filtration Group merger agreement. The 10-Q's own risk language names "uncertainties surrounding timing, successful completion or integration of acquisitions and similar transactions, including the pending acquisition of Filtration Group."
• A break below the 200-day moving average of $909.54 on company-specific news.

Pre-registered FLIP conditions — what would take this to Buy — Tactical:

• Price below approximately $880 (roughly 23.4x FY2028E, 25.8x FY2027E) with no deterioration in backlog or Aerospace margin. At $880 the base case is +13.6% and the risk/reward inverts. That is 11.4% below today's close.
• An FY2027 guide above roughly $23.0B of revenue or $35.00 of adjusted EPS on 2026-08-06, which would put the FY2028 consensus high of $40.78 in play and make the current multiple defensible on growth rather than on hope.
• Filtration Group closing with the majority of consideration termed out into long-dated senior notes at a manageable coupon, converting the single largest open risk into a known cost.
• Aerospace Systems margin printing above 26% with backlog above $8.5B, which would argue the mix shift has further to run.
• Genuine name-level knowledge-base conviction appearing — a claim about Parker's aerospace franchise, its capital allocation, or the Filtration Group deal, rather than about a basket containing Parker. At present there is none.

Where PH fits in the Synthos Framework Portfolio. The industrial / aerospace-supply-chain sleeve, at 0% today with a 1.5% target on a fill near $880 or a confirmed FY2027 guide above $23B. Batch overlap note: Howmet Aerospace (HWM) is in this batch and in Parker's own vendor peer set, and the two share the commercial-aerospace aftermarket driver. They are not the same trade — Howmet is engineered products at the engine and airframe structural level with no industrial half — but a reader holding both is doubling the aerospace-build-rate exposure and should size accordingly. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $992.65.

Single biggest risk: the Filtration Group financing. $9.25 billion of cash consideration against $3.3 billion of annual free cash flow and $476 million of cash on hand, funded by $5.25 billion of 364-day and $2.50 billion of three-year term money, on a balance sheet whose tangible equity is already negative $3.912 billion and whose intangibles are 60.4% of assets. Every screen a reader can consult shows 1.62x leverage. The filing shows a signed merger agreement and $7.75 billion of committed facilities. If the industrial cycle softens between the draw and the refinancing, Parker will be terming out $5.25 billion of paper into whatever market exists at that moment, with a 70-year dividend record it will not want to break and a buyback it will almost certainly have to cut. That is the risk the price does not carry, because the price cannot see it.

Provenance & disclosures

• Traceability: 3 raw knowledge-base hits name Parker-Hannifin by entity (entity matches 3, text matches 0, distinct claims after de-duplication 2, discarded for collision 6; breadth 2, net conviction positive-low). Sources: jordi_visser (1 claim, 2025-07-20, bullish, conviction 92, horizon thesis, no named speaker, speaker_role: independent — a six-name megacap energy/industrial basket listing PH alongside XOM, CVX, FCX, CAT and DE) and compound_and_friends (2 claims, both 2026-02-27, both bullish, conviction 70, no named speaker, the same observation recorded twice — AI-derivative industrials naming Carrier, Trane, Quanta Services and Parker Hannifin). Neither distinct claim is about Parker-Hannifin as a company; both are basket calls, and this is stated as a finding rather than padded. A concentration sensitivity test was run because compound_and_friends supplies 67% of raw hits: removing that channel leaves the jordi_visser basket claim and does not change the conclusion. No claim in the lane carries a management speaker_role, so the half-weight management discount does not apply. Homograph discards, 6 total: five text matches on "Parker" — four Warby Parker (eyewear; one business_breakdowns claim on its DTC model, three claims about Android XR smart-glasses partnerships, in which the named AI assistant is redacted per house rules) and one Adam Parker, a named sell-side strategist cited in a claim about Uber — plus one case-sensitive text match on standalone "PH" in an arthur_hayes claim from 2023-10-17 where PH means petahash. An entity sweep on "Filtration Group" returned zero hits. All quotes are verbatim from the stored claim text.
• Data as-of: most recent filing-verified financials 2026-03-31, from the 10-Q filed 2026-05-01 (income statement, balance sheet, cash flow, segment tables, backlog, debt and acquisition disclosures) · annual statements FY2025 ended 2025-06-30 from inc_a/bal_a/cf_a, corroborated by the 10-K filed 2025-08-22 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873603 = 2026-08-04T20:00:03Z ($992.65, −0.49%; 50-DMA $935.02; 200-DMA $909.54; RSI 63.7; MACD +11.98) · knowledge-base claims 2026-08-04. Fiscal/calendar note: Parker's fiscal year ends 30 June. "FY2026" means the twelve months to 2026-06-30, and the fourth quarter of that year has NOT yet been reported — it is released 2026-08-06. All figures come from the Synthos vendor data file for PH or from the SEC filings in the PH archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2025-08-22 (fiscal 2025); 10-Q filed 2026-01-30 (December 2025 quarter); 10-Q filed 2026-05-01 (March 2026 quarter); 8-K filed 2026-01-29 (Q2 FY2026 results — cover document only, Exhibit 99.1 not extracted); 8-K filed 2026-03-17 (director Kevin A. Lobo will not stand for re-election, citing his election to the GE HealthCare board, explicitly not a disagreement); 8-K filed 2026-04-30 (Q3 FY2026 results — cover document only). All three 8-Ks were read in full. Two are earnings-release covers containing no financial data; one is a routine director-departure notice. No corporate action postdating the statements appears in the 8-K archive — the $9.25B Filtration Group transaction was found in the 10-Q, not the 8-Ks, because the announcing 8-K of 2025-11-12 predates the three retained in this archive.
• Where the filings contradicted or corrected the vendor (detailed in Section 8): the $9.25B pending all-cash acquisition of Filtration Group Corporation and the $7.75B of committed delayed-draw term loans appear in no vendor field whatsoever, and pro-forma net debt of roughly $18.4B against the reported $9.106B is presented alongside the reported figure with both labelled; bal_a FY2025 totalDebt of $9,640M rejected in favour of the 10-Q's $9,285M (a $355M finance-lease classification gap); est.ebitdaAvg and est.ebitAvg rejected in full as fixed-ratio fabrications at exactly 36.70% and 31.45% of revenue in every year, running 33-46% above reported actuals; lastDividend of $7.40 identified as the TTM total rather than the last declared dividend, with the 10-Q giving $1.80 (January 2026) and $2.00 (April 2026) and therefore an $8.00 forward run-rate; quote.yearHigh/yearLow rejected in favour of tech.hi52/lo52; trailing EBITDA presented on both the vendor's pre-tax basis ($5,629M) and a stricter operating basis ($5,309.5M) because the former includes roughly $353M of non-operating other income. Where vendor and filing AGREED — worth recording: enterpriseValueTTM of $134,265,654,041 is market capitalisation plus exactly the 10-Q's $9,106M of 31 March 2026 net debt; seg_prod sums to $19,850M for FY2025, matching reported revenue to the dollar, with both reportable segments correctly named; seg_geo sums to $19,850M with the 67.5% North American home market present; the FY2023 acquisitionsNet of −$6,672,903,000 matches the Meggitt purchase; inc_q revenue and operating income for the March 2026 quarter match the 10-Q income statement exactly.
• Basis note: analyst estimates and earn_cal actuals are adjusted (non-GAAP); reported diluted EPS is GAAP, and the gap is wide — trailing adjusted EPS is $30.73 against trailing diluted GAAP of $27.10, a 13.4% difference driven principally by acquisition-related intangible amortisation. The earn_cal basis is consistent across all five reported quarters in the file — actual and estimate are both adjusted in every row — so the beat series (+3.3%, +8.3%, +9.1%, +6.8%, +4.2%) is a like-for-like comparison and no PLD-style mid-series basis switch is present. Forward multiples in this dive use consensus adjusted EPS; the trailing multiple is shown on both bases (32.3x adjusted, 36.6x GAAP diluted).
• Estimate coverage: 18 analysts on FY2026 revenue and 16 on FY2026 EPS; 16 and 14 on FY2027; 12 and 6 on FY2028; 3 and ONE on FY2029; 2 and ONE on FY2030. FY2029 and FY2030 are excluded from every conclusion. The FY2028 EPS row, on which the fair-value anchors rest, carries six analysts, and that thinness is disclosed rather than buried.
• Consensus-basis caveat: we infer, and label as inference, that published consensus revenue does not include Filtration Group — $22.714B for FY2027 is +6.5% on FY2026E, a rate inconsistent with adding a business that costs $9.25B. If the deal closes inside fiscal 2027, the revenue, interest-expense and share-count lines all change basis and every forward multiple in this dive is computed on a company that will no longer exist in that form.
• Peer note: the vendor peer set contains a reasonable industrial cohort — Cummins ($87.8B), Emerson ($89.0B), Illinois Tool Works ($84.9B), Trane ($103.9B), 3M ($93.6B) — plus three defence primes (General Dynamics, Lockheed Martin, Northrop Grumman), Howmet Aerospace ($115.3B), which is also in this batch, and ADP, which is not a comparable. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn.
• Fair-value caveat: the $730 / $1,000 / $1,225 anchors are multiples of the FY2028 consensus adjusted-EPS distribution — 21x the low of $34.653, 26.6x the mean of $37.587, and 30x the high of $40.778 — cross-checked against the better-covered FY2027E of $34.059 (14 analysts). Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 25x gives $940, 28x gives $1,052. All three anchors are struck on a pre-Filtration-Group earnings stream, because that is what consensus supplies; a closed acquisition would require restriking all three.
• Timing: fiscal 2026 fourth-quarter and full-year results are released 2026-08-06, TWO DAYS after this dive. Consensus is adjusted EPS $8.26 and revenue $5,573.7M. The verdict is set with that timing as an explicit input, and the dive states plainly that entering 48 hours ahead of a fiscal-year-end print and first annual guide, at the 91st percentile of the annual range, is not an entry with an edge in it.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.